Drug Safety

, Volume 32, Issue 4, pp 335–343 | Cite as

Iatrogenic Effects of COX-2 Inhibitors in the US Population

Findings from the Medical Expenditure Panel Survey
  • Rhema Vaithianathan
  • Peter M. Hockey
  • Thomas J. Moore
  • David W. Bates
Original Research Article

Abstract

Background: Selective cyclo-oxygenase 2 inhibitors (‘coxibs’) have been demonstrated to increase cardiovascular risk, but the cumulative burden of adverse effects in the US population is uncertain.

Objective: To quantify cardiovascular and gastrointestinal (GI) haemorrhage disease burden from coxibs and traditional ‘non-selective’ non-steroidal anti-inflammatory drugs (t-NSAIDs) in the US population.

Design, setting and participants: Adult respondents from the 1999–2003 Medical Expenditure Panel Survey, a representative sample of the US population which first became available in December 2006, were included. Respondents were followed for 2 years. Exposure was defined by two or more prescriptions of rofecoxib, celecoxib or a t-NSAID in the first year.

Main outcome measures: Acute myocardial infarction (AMI), stroke and/or GI haemorrhage in the year following exposure.

Results: Exposure to rofecoxib was associated with an adjusted odds ratio (OR) of 3.30 for AMI (95% CI 1.41, 7.68; p = 0.01) and 4.28 for GI haemorrhage (95% CI 1.33, 13.71; p = 0.02). Celecoxib was not associated with a statistically significant effect on AMI (OR 1.44; 95% CI 0.57, 3.69; p = 0.44), but there was an OR of 2.43 for stroke (95% CI 1.05, 5.58; p = 0.04) and 4.98 for GI haemorrhage (95% CI 2.22, 11.17; p<0.001). The group of t-NSAIDs was not associated with a significant adverse effect on AMI (OR 1.47; 95% CI 0.76, 2.84; p = 0.25) or stroke (OR 1.26; 95% CI 0.42, 3.81; p= 0.68), and was associated with an OR of 2.38 for GI haemorrhage (CI 1.04, 5.46; p = 0.04). In the 1999–2004 period rofecoxib was associated with 46 783 AMIs and 31 188 GI haemorrhages; celecoxib with 21 832 strokes and 69 654 GI haemorrhages; resulting in an estimated 26 603 deaths from both coxibs. The t-NSAID group was associated with an excess of 87 327 GI haemorrhages and 9606 deaths in the same period.

Conclusions: Iatrogenic effects of coxibs in the US population were substantial, posing an important public health risk. Drugs that were rapidly accepted for assumed safety advantages proved instead to have caused substantial injury and death.

Notes

Acknowledgements

Peter Hockey and Rhema Vaithianathan acknowledge funding from the Commonwealth Fund of New York and the Health Foundation, London (Peter Hockey). The Commonwealth Fund and Health Foundation played no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. Rhema Vaithianathan, Peter Hockey and David Bates have no conflict of interests. Thomas Moore has worked as a consultant to plaintiffs’ lawyers and Federal court-supervised lawyers’ committees in the rofecoxib, celecoxib and valdecoxib litigation. Rhema Vaithianathan had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

  1. 1.
    US Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. April 6, 2005 [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecisionMemo.pdf [Accessed 2008 Jan 29]
  2. 2.
    Agency for Healthcare Research and Quality. Prescribed drug estimates: 2005. Medical Expenditure Panel Survey [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/data_stats/summ_tables/hc/drugs/2005/hcdrugest_totpur2005.shtml [Accessed 2008 Mar 6]
  3. 3.
    Pfizer reports fourth-quarter and full-year 2007 results and 2008 financial guidance [online]. Available from URL: http://www.drugs.com/news/pfizer-reports-fourth-quarter-full-year-2007-results-2008-financial-guidance-7630.html [Accessed 2008 Mar 1]
  4. 4.
    Andersohn F, Schade R, Suissa S, et al. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006 Jul; 37(7): 1725–30PubMedCrossRefGoogle Scholar
  5. 5.
    Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352(11): 1092–102PubMedCrossRefGoogle Scholar
  6. 6.
    Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006 Jun 27; 113(25): 2906–13PubMedCrossRefGoogle Scholar
  7. 7.
    Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 Feb 5–11; 365(9458): 475–81PubMedGoogle Scholar
  8. 8.
    Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other t-NSAIDs: a population-based case-control study. Arch Intern Med 2005 May 9; 165(9): 978–84PubMedCrossRefGoogle Scholar
  9. 9.
    Chin A, Commerford P. Non-steroidal anti-inflammatory drugs and cardiovascular risk. S Afr Med J 2007 Jul; 97(7): 500–3PubMedGoogle Scholar
  10. 10.
    Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. March 22, 2007; response rates by panel [online]. Available from URL: http://www.meps.ahrq.gov/mepsweb/survey_comp/hc_response_rate.jsp [Accessed 2008 Mar 6]
  11. 11.
    Bertoni AG, Bonds DE, Thom T, et al. Acute coronary syndrome national statistics: challenges in definitions. Am Heart J 2005 Jun; 149(6): 1055–61PubMedCrossRefGoogle Scholar
  12. 12.
    Goldberg RJ, Yarzebski J, Lessard D, et al. A two-decades (1975 to 1995) long experience in the incidence, in-hospital and long-term case-fatality rates of acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999 May; 33(6): 1533–9PubMedCrossRefGoogle Scholar
  13. 13.
    Syme PD, Byrne AW, Chen R, et al. Community-based stroke incidence in a Scottish population: the Scottish Borders Stroke Study. Stroke 2005 Sep; 36(9): 1837–43PubMedCrossRefGoogle Scholar
  14. 14.
    Roberts SE, Goldacre MJ. Case fatality rates after admission to hospital with stroke: linked database study. BMJ 2003 Jan 25; 326(7382): 193–4PubMedCrossRefGoogle Scholar
  15. 15.
    Thomsen RW, Riis A, Christensen S, et al. Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Aliment Pharmacol Ther 2006 Nov 15; 24(10): 1431–8PubMedCrossRefGoogle Scholar
  16. 16.
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343(21): 1520–8PubMedCrossRefGoogle Scholar
  17. 17.
    Graham DJ. COX-2 inhibitors, other t-NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006 Oct 4; 296(13): 1653–6PubMedCrossRefGoogle Scholar
  18. 18.
    Helin-Salmivaara A, Saarelainen S, Gronroos JM, et al. Risk of upper gastrointestinal events with the use of various t-NSAIDs: a case-control study in a general population. Scand J Gastroenterol 2007 Aug; 42(8): 923–32PubMedCrossRefGoogle Scholar
  19. 19.
    Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Dec 3; 331(7528): 1310–6PubMedCrossRefGoogle Scholar
  20. 20.
    Depont F, Fourrier A, Merliere Y, et al. Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and t-NSAIDs description of users (CADEUS) study. Pharmacoepidemiol Drug Saf 2007 Aug; 16(8): 891–900PubMedCrossRefGoogle Scholar
  21. 21.
    MacDonald TM, Morant SV, Goldstein JL, et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003 Sep; 52(9): 1265–70PubMedCrossRefGoogle Scholar
  22. 22.
    American Heart Association. Heart attack and angina statistics [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=4591 [Accessed 2008 Mar 6]
  23. 23.
    Solomon SD, Wittes J, Finn PV, et al. Caridiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 2008; 117: 2104–13PubMedCrossRefGoogle Scholar
  24. 24.
    Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 2007 Sep 10; 167(16): 1752–9PubMedCrossRefGoogle Scholar
  25. 25.
    Fatality analysis reporting system encyclopedia [online]. Available from URL: http://www-fars.nhtsa.dot.gov/Main/index.aspx [Accessed 2008 Feb 20]

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Rhema Vaithianathan
    • 1
  • Peter M. Hockey
    • 2
  • Thomas J. Moore
    • 3
  • David W. Bates
    • 2
  1. 1.Department of EconomicsUniversity of AucklandAucklandNew Zealand
  2. 2.Division of General MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  3. 3.Institute for Safe Medication PracticesAlexandriaUSA

Personalised recommendations